Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson’s and Rare Epilepsy Research

Lunai Bioworks' subsidiary BioSymetrics and BrainStorm Therapeutics have entered a collaboration to discover and advance new therapeutic targets for neurological diseases, announced in a press release. The partnership is supported by a grant from the LouLou Foundation.

The collaboration combines BioSymetrics' AI discovery and zebrafish validation systems with BrainStorm’s human-derived organoid models. The goal is to create an integrated framework for neurology drug discovery and generate validated therapeutic programs suitable for pharmaceutical development and licensing.

Initial research will target rare genetic epilepsies and neurodegenerative diseases such as Parkinson’s disease. The teams will integrate BrainStorm’s midbrain organoid model with BioSymetrics’ analysis of the Parkinson’s Progression Markers Initiative dataset to identify progression-linked biomarkers and actionable therapeutic targets.

A flagship project under the collaboration, involving Brigham and Women’s Hospital and Harvard Medical School, will focus on developing treatments for a rare genetic epilepsy. The companies have also signed a Letter of Intent to expand the collaboration to additional neurological indications, with a structured plan for target identification, validation, and partnership development.